Acquired defects of fibrinolysis associated with thrombosis.

abstract：:Most acute coronary syndromes result from a platelet-rich occlusion of the coronary arteries. Antiplatelet drugs are of proven efficacy in preventing myocardial infarction, unstable angina, and stroke. However, not all patients on aspirin (ASA) benefit. We studied the phenomenon of aspirin resistance with a simple and...

journal_title：Seminars in thrombosis and hemostasis

authors： Crowe B,Abbas S,Meany B,de Haan J,Cahill MR

更新日期：2005-01-01 00:00:00

abstract：:Patients treated with oral anticoagulants (OAC) carry a 7- to 10-fold higher risk of intracerebral hemorrhage (ICH) than patients without OAC. ICH related to oral anticoagulation (OAC-ICH) is a particularly severe form of stroke. The overall incidence of OAC-ICH ranges between 2 and 9 per 100,000 population/year and i...

journal_title：Seminars in thrombosis and hemostasis

authors： Veltkamp R,Rizos T,Horstmann S

更新日期：2013-11-01 00:00:00

abstract：:Most plasma proteins are present in both normal and atherosclerotic intima, and their concentrations in intimal interstitial fluid are directly related to plasma concentration and molecular size. All intimal samples also contain soluble fibrin-fibrinogen-related antigens, consisting of variable mixtures of fibrinogen ...

journal_title：Seminars in thrombosis and hemostasis

authors： Smith EB,Crosbie L,Carey S

更新日期：1996-01-01 00:00:00

abstract：:Pathogen inactivation (PI), or pathogen reduction technology, reduces the infectious risk of plasma and platelet transfusions, and also affects clotting factor activities and platelet viabilities. Plasma is treated with solvent-detergent to disrupt enveloped viruses, or with photoactive agents methylene blue plus ligh...

journal_title：Seminars in thrombosis and hemostasis

authors： Ramsey G

更新日期：2016-03-01 00:00:00

abstract：:Severe factor XI (FXI) deficiency is an injury-related bleeding disorder common in Ashkenazi Jews and rare worldwide. In the past two decades, more than 180 mutations in the FXI gene have been reported in patients with FXI deficiency, five of which show a founder effect (Cys38Arg, Gln88Stop, Cys128Stop, Glu117stop, an...

journal_title：Seminars in thrombosis and hemostasis

authors： Duga S,Salomon O

更新日期：2009-06-01 00:00:00

abstract：:In order to assess inhibitor development in previously untreated patients (PUPs) with severe (factor VIII [FVIII]<1%) and moderate (FVIII 1 to 5%) hemophilia A, a prospective study was initiated in 1976. During the 23-year study period, 72 hemophiliacs were frequently exposed prophylactically or on demand to plasma-de...

journal_title：Seminars in thrombosis and hemostasis

authors： Kreuz W,Ettingshausen CE,Zyschka A,Oldenburg J,Saguer IM,Ehrenforth S,Klingebiel T

更新日期：2002-06-01 00:00:00

abstract：:Natural inhibitors of coagulation, in other words, antithrombin (AT), the protein C system, and tissue factor pathway inhibitor (TFPI), play an important role in controlling the activation of coagulation during disseminated intravascular coagulation (DIC). Furthermore, they may not only influence coagulation but also ...

journal_title：Seminars in thrombosis and hemostasis

authors： de Jonge E,van der Poll T,Kesecioglu J,Levi M

更新日期：2001-12-01 00:00:00

abstract：:This study aimed to determine the impact of major hemorrhage (MH) protocol (MHP) activation on blood administration and patient outcome at a UK major cardiothoracic center. MH was defined in patients (> 16 years) as those who received > 5 units of red blood cells (RBCs) in < 4 hours, or > 10 units in 24 hours. Data we...

journal_title：Seminars in thrombosis and hemostasis

authors： Chang KW,Owen S,Gaspar M,Laffan M,Arachchillage DRJ

更新日期：2021-02-01 00:00:00

abstract：:Heparin, a sulfated polysaccharide belonging to the family of glycosaminoglycans, was discovered in the beginning of the 20th century and was initially identified as a procoagulant isolated from liver tissue. After the first application in patients approximately 30 years later, further purification identified the majo...

journal_title：Seminars in thrombosis and hemostasis

authors： Harenberg J,Casu B,Krämer R,Torri G,Naggi A,Krämer S

更新日期：2014-11-01 00:00:00

abstract：:Coagulation management requires the balancing of different components that contribute to clot formation. These components include the interactions between platelets, procoagulant, anticoagulant, and fibrinolytic factors. The cause of bleeding or thrombotic events is often multifactorial; however, the tests clinicians ...

journal_title：Seminars in thrombosis and hemostasis

authors： Wegner J,Popovsky MA

更新日期：2010-10-01 00:00:00

abstract：:Vatreptacog alfa is a genetically engineered variant of recombinant factor VIIa (rFVIIa) containing three amino acid changes. Aspartic acid, valine, and glutamine residues replace valine, glutamic acid, and methionine at positions 158, 296, and 298, respectively. These substitutions result in considerable enhancement ...

journal_title：Seminars in thrombosis and hemostasis

authors： Persson E,Olsen OH,Bjørn SE,Ezban M

更新日期：2012-04-01 00:00:00

abstract：:In the early 1980s, the first external quality assessment schemes (EQAS) regarding parameters of the coagulation laboratory were established in the daily routine of German laboratories. At present, the EQAS performed by INSTAND offers a wide range of global and single parameters of thrombosis and hemostasis. Only the ...

journal_title：Seminars in thrombosis and hemostasis

authors： Spannagl M,Dick A,Reinauer H

更新日期：2007-04-01 00:00:00

abstract：:Clinical and laboratory data of children with von Willebrand disease (VWD) types have been derived from retrospective studies and small case series. This article reports on the clinical and laboratory data of a large pediatric cohort in one single Argentinian center. The biological and clinical responses to desmopress...

journal_title：Seminars in thrombosis and hemostasis

authors： Bonduel M,Frontroth JP,Hepner M,Sciuccati G,Feliu-Torres A,Pieroni G

更新日期：2011-07-01 00:00:00

abstract：:Thrombotic events are very frequent and represent the main cause of morbidity and mortality in patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), mainly polycythemia vera and essential thrombocythemia. Pathogenesis of blood clotting activation in these diseases is multifactorial, and i...

journal_title：Seminars in thrombosis and hemostasis

authors： Falanga A,Marchetti M

更新日期：2014-04-01 00:00:00

abstract：:The risk for both arterial and venous thrombosis increases with age. Despite the increasing burden of strokes related to atrial fibrillation (AF) and venous thromboembolism (VTE) among older adults, the use of anticoagulant therapy is limited in this population due to the parallel increase in risk of serious hemorrhag...

journal_title：Seminars in thrombosis and hemostasis

authors： Ko D,Hylek EM

更新日期：2014-09-01 00:00:00

abstract：:We have explored the molecular basis of the clinical therapeutic effect of factor VIIa in hemophilia A using empirical reconstituted in vitro thrombin generation models. Tissue factor acts as a receptor and activator of preexistent but virtually inactive two-chain plasma factor VIIa. However, most of the factor VII ci...

journal_title：Seminars in thrombosis and hemostasis

authors： van't Veer C,Mann KG

更新日期：2000-01-01 00:00:00

abstract：:Thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS) are thrombotic microangiopathies (TMAs) that can present in pregnancy. The presentation can be with typical microangiopathic features and thrombocytopenia, but there is also a significant risk of in-utero fetal loss. TTP presents m...

journal_title：Seminars in thrombosis and hemostasis

authors： Scully M

更新日期：2016-10-01 00:00:00

abstract：:In the past two decades, major improvements in antibiotics and other elements of supportive care have decreased the number and severity of complications of hematopoietic stem cell transplantation (HSCT). Despite these improvements, many subpopulations of transplant patients still have a significant morbidity and morta...

journal_title：Seminars in thrombosis and hemostasis

authors： Haire WD

更新日期：1999-01-01 00:00:00

abstract：:Thrombotic microangiopathy (TMA) after hematopoietic stem-cell transplantation (HSCT) or solid-organ transplantation is a serious complication that may be associated with diverse clinical conditions. The reported incidence varies widely, in part due to different diagnostic criteria. Currently, the diagnosis is based m...

journal_title：Seminars in thrombosis and hemostasis

authors： Qu L,Kiss JE

更新日期：2005-12-01 00:00:00

abstract：:The identification of the JAK2 V617F mutation in patients with myeloproliferative disorders (MPDs) represents a major breakthrough in our understanding of the pathogenesis of these diseases. One year after its discovery, an impressive number of publications appeared. These articles confirmed most of the initial result...

journal_title：Seminars in thrombosis and hemostasis

authors： Villeval JL,James C,Pisani DF,Casadevall N,Vainchenker W

更新日期：2006-06-01 00:00:00

abstract：:We investigated the protective effects of DX-9065a, an orally active, newly synthesized, and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation (DIC) in rats. Experimental DIC was induced by a 4 hour sustained infusion of thromboplastin at a dose of 2.5 mg/kg. The rats were or...

journal_title：Seminars in thrombosis and hemostasis

authors： Yamazaki M,Asakura H,Aoshima K,Saito M,Jokaji H,Uotani C,Kumabashiri I,Morishita E,Ikeda T,Matsuda T

更新日期：1996-01-01 00:00:00

abstract：:Currently, in Germany, there is a successful program where patients monitor their own coagulation status through self-testing. The advent of a new generation of coagulometers has allowed more and more patients to use self-testing to monitor their coagulation status. The development of a structured training program by ...

journal_title：Seminars in thrombosis and hemostasis

authors： Taborski U,Müller-Berghaus G

更新日期：1999-01-01 00:00:00

abstract：:von Willebrand disease (VWD) was first described nearly a century ago in 1924 by Erik Adolf von Willebrand. Diagnostic testing at the time was very limited and it was not until the mid to late 1900s that more tests became available to assist with the diagnosis and classification of VWD. Two of these tests are based on...

journal_title：Seminars in thrombosis and hemostasis

authors： Just S

更新日期：2017-02-01 00:00:00

abstract：:The pharmacokinetics of heparin differ markedly from those of its fractions both in man and in experimental animal models. The route of administration determines the relative availability of different molecular species that exert the anti-Xa, anti-IIa, fibrinopeptide A generation inhibiting actions and the release of ...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Walenga JM,Williamson K,Emanuele RM,Kumar A,Hoppensteadt DA

更新日期：1985-01-01 00:00:00

abstract：:The number of hip fractures in anticoagulated patients is predicted to increase, due to people living longer. However, evidence regarding urgent perioperative management of elderly patients with hip fracture who take oral anticoagulants (vitamin K antagonists or direct oral anticoagulants) is scarce. In this article, ...

journal_title：Seminars in thrombosis and hemostasis

authors： Grandone E,Ostuni A,Tiscia GL,Marongiu F,Barcellona D

更新日期：2019-03-01 00:00:00

abstract：:The bidirectional interaction between coagulation and inflammation, which is relevant in various disease states that are dominated by systemic inflammatory responses, such as severe infection or chronic vascular disease, is modulated by metabolic factors. Changes in lipoprotein metabolism affect the inflammation-induc...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M,Nieuwdorp M,van der Poll T,Stroes E

更新日期：2008-02-01 00:00:00

abstract：:Platelet-lowering therapy in myeloproliferative disorders includes cytostatic drugs, mainly hydroxyurea, interferon alpha, and anagrelide. Anagrelide is the latest addition to the therapeutic arsenal, and the basis for its use is reviewed. The platelet-lowering efficacy is 70 to 80% in essential thrombocythemia, and t...

journal_title：Seminars in thrombosis and hemostasis

authors： Birgegard G

更新日期：2006-04-01 00:00:00

abstract：:With the strides being made in the European, Canadian, and American prospective studies of von Willebrand disease (VWD) genotype and phenotype, genetics is increasingly playing a key role in the classification, understanding, and management of VWD. It is anticipated that as gene sequencing becomes easier and more comm...

journal_title：Seminars in thrombosis and hemostasis

authors： Novelli EM,Ragni MV

更新日期：2008-09-01 00:00:00

abstract：:Recent evidence suggests that lupus anticoagulants are immunologically distinct from the anticardiolipin antibodies. Nevertheless, the associated clinical complications exhibited by the two groups of antibodies are similar. They have been shown to have a strong association with a history of arterial and venous thrombo...

journal_title：Seminars in thrombosis and hemostasis

authors： Kampe CE

更新日期：1994-01-01 00:00:00

abstract：:Each bone marrow megakaryocyte (MK) releases thousands of platelets into the circulation, and the underlying molecular and cellular mechanisms recently have received intense scrutiny. Genetic studies are beginning to clarify the mechanisms by which transcription factors help distinguish MK progenitors from other blood...

journal_title：Seminars in thrombosis and hemostasis

authors： Schulze H,Shivdasani RA

更新日期：2004-08-01 00:00:00